HBV Partnerships Leverage Brii Bio's active HBV program portfolio and existing global licensing activity (notably with VBI and Asia-Pacific expansion) to propose co-development, licensing, or regional commercialization opportunities that align with their strategic focus on hepatitis B therapies.

Asia-Pacific Focus Target BD efforts in the Asia-Pacific region where Brii Bio has exclusive development and commercialization rights for key HBV assets, presenting partnerships with local manufacturing, distribution, or clinical trial support to accelerate market entry.

Strategic Alliances Position collaborative opportunities with Joincare Pharmaceutical Group and other potential Chinese and APAC partners to bolster late-stage development, manufacturing scale, and access to diverse patient populations for ENSURE-like HBV trials.

Clinical Data Enablement Offer services or partnerships that enhance Brii Bio's trial programs (e.g., ENSURE) through CRO networks, data management, and real-world evidence generation to de-risk and accelerate regulatory milestones and potential approvals.

Manufacturing & IP Propose manufacturing support, supply chain resilience, and IP exploitation collaborations around their growing asset base (HBV vaccines and therapeutics) to reduce costs, improve scalability, and protect competitive positioning.